Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Long-Term Investments (2021 - 2023)

AVITA Medical's Long-Term Investments history spans 3 years, with the latest figure at $2.8 million for Q2 2023.

  • For Q2 2023, Long-Term Investments fell 59.16% year-over-year to $2.8 million; the TTM value through Jun 2023 reached $2.8 million, down 59.16%, while the annual FY2022 figure was $6.9 million, N/A changed from the prior year.
  • Long-Term Investments reached $2.8 million in Q2 2023 per RCEL's latest filing, down from $4.2 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $19.8 million in Q3 2021 to a low of $2.8 million in Q2 2023.
  • Average Long-Term Investments over 3 years is $9.5 million, with a median of $6.8 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: crashed 79.74% in 2022, then plummeted 59.16% in 2023.
  • A 3-year view of Long-Term Investments shows it stood at $19.7 million in 2021, then tumbled by 64.81% to $6.9 million in 2022, then crashed by 60.26% to $2.8 million in 2023.
  • Per Business Quant, the three most recent readings for RCEL's Long-Term Investments are $2.8 million (Q2 2023), $4.2 million (Q1 2023), and $6.9 million (Q4 2022).